carbazilquinone has been researched along with Myeloproliferative Disorders in 1 studies
Carbazilquinone: An alkylating agent structurally similar to MITOMYCIN and found to be effective in the treatment of leukemia and various other neoplasms in mice. It causes leukemia and thrombocytopenia in almost all human patients.
Myeloproliferative Disorders: Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Niikura, H | 1 |
1 review available for carbazilquinone and Myeloproliferative Disorders
| Article | Year |
|---|---|
[Thrombosis in various diseases: myeloproliferative disorders].
Topics: Aspirin; beta-Thromboglobulin; Blood Coagulation Factors; Busulfan; Carbazilquinone; Dipyridamole; H | 1986 |